Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epalolitoworelimab (PD-1/CTLA-4 antibody) plus lenvatinib perioperative therapy in high-risk localized and locally advanced clear cell renal cell carcinoma
ChiCTR2600128849Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 and lenvatinib in clear cell renal cell carcinoma (ccRCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Objective Response Rate, 12-month disease-free survival rate and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
QL1706lenvatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2600128849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128849.